Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody

$Mouse liver lysate probed with Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody (bsm-52695R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Mouse liver lysate probed with Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody (bsm-52695R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody (bsm-52695R) at 1:100 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody (bsm-52695R) at 1:100 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody (bsm-52695R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody (bsm-52695R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human kidney tissue incubated with Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody (bsm-52695R) at 1:300, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human kidney tissue incubated with Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody (bsm-52695R) at 1:300, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse ovary tissue incubated with Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody (bsm-52695R) at 1:300, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse ovary tissue incubated with Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody (bsm-52695R) at 1:300, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
FCM
IHC-P
IF(ICC)
IHC

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-52695R
Product Name	Ubiquitin-like modifier-activating enzyme 1 (8A4) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(ICC), IHC
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Human Ubiquitin-like modifier-activating enzyme 1 between 1000 amino acids to C-terminus
Clonality	Monoclonal
Clone #	8A4
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	7317
Swiss Prot	P22314
Synonyms	Ubiquitin-like modifier-activating enzyme 1, Protein A1S9, Ubiquitin-activating enzyme E1, UBA1
Background	Catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation through the ubiquitin-proteasome system (PubMed:1606621, PubMed:1447181). Activates ubiquitin by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a ubiquitin-E1 thioester and free AMP (PubMed:1447181). Essential for the formation of radiation-induced foci, timely DNA repair and for response to replication stress. Promotes the recruitment of TP53BP1 and BRCA1 at DNA damage sites (PubMed:22456334).
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC

Applications

Reactivity

Search our catalog of hundreds of thousands of products